

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND
CHANGE IN THE COMPOSITION OF BOARD COMMITTEES**

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Wai Chun Bio-Technology Limited (the “**Company**”) hereby announces that Mr. Hau Pak Man (“**Mr. Hau**”) has resigned as an independent non-executive director of the Company with effect from 10 October 2022 in order to devote more time to his personal commitments.

Mr. Hau has confirmed that he has no disagreement with the Board and there is no matter that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) in respect of his resignation.

The Board would like to take this opportunity to express its gratitude to Mr. Hau for his efforts and valuable contributions to the Company during his term of office with the Company.

CHANGE IN THE COMPOSITION OF BOARD COMMITTEES

The Board also announces that with effect from 10 October 2022:

Mr. Hau has ceased to be the member of each of the audit committee and nomination committee of the Company, and the member and chairman of the remuneration committee of the Company.

Ms. Hong Ting, an independent non-executive director of the Company, has been appointed as the chairman of the remuneration committee of the Company.

Following the resignation of Mr. Hau and as at the date of this announcement:

- (i) the Board comprises three members with one executive director and two independent non-executive directors; and
- (ii) the audit committee of the Company comprises only two members.

It results in non-compliance with the requirements under Rules 3.10(1) and 3.21 of the Rules Governing the Listing of Securities (“**Listing Rules**”) on the Stock Exchange. The Company is in the process of identifying suitable candidate to fill the vacancy and will use its best endeavours to ensure that suitable candidate is appointed as soon as practicable and in any event within three months from 10 October 2022 as required under Rule 3.11 of the Listing Rules. Further announcements will be made by the Company as and when appropriate.

By Order of the Board
Wai Chun Bio-Technology Limited
Chan Cheuk Ho
Executive Director

Hong Kong, 10 October 2022

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Chan Cheuk Ho and two independent non-executive Directors, namely Mr. Wan Bo and Ms. Hong Ting.